Redwood Investment Management LLC acquired a new stake in West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 3,283 shares of the medical instruments supplier’s stock, valued at approximately $1,179,000.
Other institutional investors also recently added to or reduced their stakes in the company. Proficio Capital Partners LLC purchased a new stake in West Pharmaceutical Services during the 2nd quarter worth about $381,000. Transamerica Financial Advisors LLC acquired a new stake in shares of West Pharmaceutical Services during the second quarter worth $87,000. Corient Private Wealth LP purchased a new stake in West Pharmaceutical Services in the 2nd quarter valued at about $23,607,000. Ausdal Financial Partners Inc. purchased a new position in shares of West Pharmaceutical Services during the 2nd quarter worth about $289,000. Finally, Bamco Inc. NY acquired a new stake in shares of West Pharmaceutical Services in the second quarter worth approximately $58,938,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.
West Pharmaceutical Services Stock Performance
Shares of West Pharmaceutical Services stock opened at $350.68 on Thursday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.12 and a current ratio of 2.82. West Pharmaceutical Services, Inc. has a 1 year low of $223.83 and a 1 year high of $386.00. The firm’s 50-day simple moving average is $349.99 and its 200-day simple moving average is $302.68. The firm has a market cap of $24.68 billion, a PE ratio of 44.90, a price-to-earnings-growth ratio of 2.44 and a beta of 1.15.
West Pharmaceutical Services Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th were paid a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date was Wednesday, July 29th. West Pharmaceutical Services’s dividend payout ratio is presently 11.27%.
Analysts Set New Price Targets
Several research firms have recently weighed in on WST. Wolfe Research began coverage on West Pharmaceutical Services in a research note on Monday, June 1st. They issued an “outperform” rating and a $375.00 price objective on the stock. Barclays upgraded shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $310.00 to $400.00 in a report on Tuesday, June 9th. Citigroup lifted their price target on shares of West Pharmaceutical Services from $400.00 to $412.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Morgan Stanley boosted their price objective on shares of West Pharmaceutical Services from $325.00 to $365.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 9th. Finally, Weiss Ratings raised shares of West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $368.08.
View Our Latest Stock Report on WST
West Pharmaceutical Services Profile
West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.
In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.
Featured Stories
- Five stocks we like better than West Pharmaceutical Services
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST – Free Report).
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.
